Top Biotech Companies in Dublin (42)
Opsona Therapeutics is a leading drug development company specialising in the human immune system. Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline...
Astrix is the unrivaled market-leader in creating & delivering innovative strategies, solutions, and people to the life science community. Through world class people, process, and technology, Astrix works with clients to fundamentally improve business & scientific outcomes across many domains including the laboratory, clinical & regulatory, pharmacovigilance, R&D, and manufacturing. Founded by scientists to solve the unique challenges of the...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Genuity Science is a data sourcing, analytics, and insights organization that partners with global biopharma companies to provide deep end-to-end discovery services. Using purpose-driven data, genomic know-how, and an advanced AI/ML platform, the company catalyzes insights in CNS, cardiometabolic, and inflammatory diseases to accelerate drug discovery and improve precision medicine and patient quality of life globally.
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as many smaller enterprises across our spectrum of services. Having completed more than 50 submissions for drug approval over the last 5 years, we remain a top choice for sponsors who are looking for innovation and demand high quality from their CRO...
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business...
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers #SimplifyProgress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are #PartOfTheSolution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the our Lab Products & Services division focuses on laboratories performing...
Sartorius's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent market analyses repeatedly characterize Sartorius as a top‑tier leader in single‑use bioprocessing, particularly in single‑use bioreactors, bags/assemblies, and integrated upstream platforms. Broad scale from bench to 2,000‑L, a large installed base, and continued capacity expansions reinforce this position.
Strong Revenue Growth: Company disclosures indicate sales grew 7.6% in constant currencies in 2025 to about €3.54 billion, with Q1 2026 up 7.5% and full‑year 2026 guidance of 5–9% growth. Order intake recovery from late 2024 and momentum in Bioprocess Solutions underpin this trend.
Profitability: Underlying EBITDA increased faster than sales in 2025, with margin near 30%, and management expects robust margins into 2026. Improving cash generation and recurring consumables contribute to sustained profitability.
Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled...
.png)
Ancestry is the global leader in family history and consumer genomics. Every day, around the world, we help curious people like you embark on journeys of personal discovery to enrich lives. With our unparalleled collection of more than 40 billion records from more than 80 countries and 23+ million people in our growing DNA network, Ancestry helps customers discover their family...
Ancestry's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company communications and industry coverage consistently depict Ancestry as the category leader, citing tens of billions of records, millions of subscribers, and the world’s largest consumer DNA network. Blackstone’s 2020 acquisition and a weakened rival landscape (e.g., 23andMe’s 2025 bankruptcy) reinforce its durable leadership.
Product Line Growth: Content and features expanded with 243 new historical collections in 2025, the largest-ever ethnicity update, and the iMemories acquisition adding media digitization. AI-enabled processing accelerates turning archives into searchable data, signaling ongoing product and data-scale growth.
Market Expansion: The company launched services in Italy and the Netherlands in 2025 and reported strong subscriber scale alongside rising community uploads. A multiyear partnership with the U.S. National Archives supports continued content expansion that benefits multiple markets.
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe,...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
Summit Mission Statement: To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising...
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major...
We are a biotech longevity company on a mission to confront aging and age-related diseases. We’re building a coalition of the best scientists, physicians and investors to develop therapies and products that will help people experience better health for longer in their lives. We are organized to drive scientific innovation with speed and agility to market
Our Vision is to bring an Insect Farming revolution to the world, to end the overexploitation of land and ocean and to ultimately add to the progress of the human race. With revolutionary breeding and bio-conversion technologies, we maximise the extraction of high-value protein and oil products for the aquaculture, animal feed and plant nutrition industries. Our process produces no...
We are driving the future of animal health through technology that enables the agriculture industry to target treatment based on rapid, on-site diagnostics. Helping maximise yield and reduce costs all whilst helping to reduce environmental impact
Technology for sustainable and cost-effective conversion of biomass waste into clean and drop-in advanced fuels for the marine, road and aviation sectors. Fuel is produced efficiently, at low-cost and with currently 85% fewer GHGs than traditional fossil fuel production, and hard at work to achieve carbon-neutral and negative fuels. Highlights include; an operational pilot plant deployed in Spain, patented technology,...
Through pioneering life science and artificial intelligence, we developed our unique Nuritas MagnifierNπΦ platform that allows us to identify, unlock, clinically test and patent peptides; turning them into powerful and precise ingredients that elevate natural efficacy. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat,...
